Uveitis Treatment Market Size, Share, Trends, Analysis and Forecast 2020-2026


Posted October 9, 2020 by globalomr

Global Uveitis treatment Market Size, Share & Trends Analysis Report by Disease Type (Anterior Uveitis, Posterior Uveitis, Intermediate Uveitis, and Pan Uveitis) and Treatment Type and Forecast 2020-2026

 
The global uveitis treatment market is projected to exhibit a significant growth, at a CAGR of around 6.1%, during the forecast period. The increasing prevalence of uveitis with the rising autoimmune disorders and eye-related disorders have been offering growth to the uveitis treatment market. The growing government initiatives to aware population and provide better healthcare facilities are further creating enormous growth opportunities for the uveitis treatment market in the emerging nations, such as India and China. In addition, the increasing healthcare expenditure and growing medical industry will escalate the market growth during the forecast period. An increasing number of hospitals and ophthalmic clinics in emerging economies are providing immense growth opportunities for the uveitis treatment market.

A full report of Uveitis Treatment Market is available at: https://www.omrglobal.com/industry-reports/uveitis-treatment-market

Such factors have further propelled the need for advanced treatment solutions for uveitis. A new journey can be expected in the uveitis treatment market with the introduction of the novel delivery systems across the globe. This includes the introduction of Iontophoresis for the treatment of anterior uveitis. Iontophoresis refers to the use of an electric current, to propel molecules over the hydrophilic cornea epithelium, which is one of the largest roadblocks to drug penetration in an eye. This expectedly increase the bioavailability of medications, such as steroids, allowing greater reduction in the frequency doses and increase in efficiency, when compared to topical corticosteroids.

To learn more about this report request a free sample copy @ https://www.omrglobal.com/request-sample/uveitis-treatment-market

Moreover, in May 2018, Clearside Biomedical Inc. introduced novel drug therapy for the treatment of back-of-the-eye diseases. The company announced the attainment for the positive topline results from its new Phase 3 clinical trial of suprachoroidal CLS-TA in patients dealing with macular edema associated with non-infectious uveitis. As per the survey, nearly 47% of patients who were given suprachoroidal CLS-TA for around 12 weeks continuously have gained around 15 letters in best corrected visual acuity (“BCVA”), as measured using the Early Treatment of Diabetic Retinopathy Study (“ETDRS”) scale. Moreover, the trial was well tolerated, with no report of any kind of the serious adverse events during the trial.

Intravitreal Sirolimus is another treatment solution available for the uveitis. It is an immunomodulating agent that reduces the number of T-cells and inflammatory cytokines in the patient’s body. Oral sirolimus is widely used for the treatment of posterior uveitis; however, due to its certain side effects, the physicians do not recommend. There is an ongoing phase 3 study for the investigation of intravitreal sirolimus for the treatment of non-infectious posterior uveitis treatment. In addition, the intravitreal sirolimus has a lower rate of side effects as compared to intravitreal corticosteroids. Such development in the uveitis treatment solutions will drive the market growth during the forecast period.

Global Uveitis Treatment Market-Segmentation

By Disease Type

• Anterior Uveitis
• Posterior Uveitis
• Intermediate Uveitis
• Pan Uveitis

By Treatment Type

• Corticosteroids
• Immunosuppressant
• Monoclonal Antibodies
• Cycloplegic Agents
• Others (Antiviral and Antibiotics)

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/uveitis-treatment-market

Global Uveitis Treatment Market– Segment by Region

North America

• United States
• Canada

Europe

• Germany
• United Kingdom
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Middle East & Africa
• Latin America

Company Profiles

• AbbVie Inc.
• Aldeyra Therapeutics, Inc.
• Alimera Sciences, Inc.
• Allergan PLC
• Bausch Health Companies Inc.
• Cadila Pharmaceuticals Ltd.
• Clearside Biomedical, Inc.
• EyePoint Pharmaceuticals, Inc.
• Mylan NV
• Novartis AG
• Pfizer Inc.
• Prometheus Laboratories Inc.
• Santen Pharmaceutical Co., Ltd.


About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

For More Information, Visit https://www.omrglobal.com


Media Contact:

Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: [email protected]
Contact no: +91 780-304-0404
-- END ---
Share Facebook Twitter
Print Friendly and PDF DisclaimerReport Abuse
Contact Email [email protected]
Issued By Arti Sharma
Phone +91 780-304-0404
Business Address 305-308, Commerce House, Janjeerwala Square, Indore, Madhya Pradesh 452001
Country India
Categories Business , Health , Medical
Tags Health , medical , Disorder , Pharmaceuticals , healthcare
Last Updated October 9, 2020